動脈硬化性疾患予防ガイドライン 2022 年版
Saved in:
| Published in | 日大医学雑誌 Vol. 82; no. 2; pp. 71 - 76 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
日本大学医学会
01.04.2023
|
| Online Access | Get full text |
| ISSN | 0029-0424 1884-0779 |
| DOI | 10.4264/numa.82.2_71 |
Cover
| Author | 奥村, 恭男 瀬在, 明 田中, 正史 |
|---|---|
| Author_xml | – sequence: 1 fullname: 田中, 正史 organization: 日本大学医学部外科学系心臓血管外科学分野 – sequence: 1 fullname: 瀬在, 明 organization: 日本大学医学部外科学系心臓血管外科学分野 – sequence: 1 fullname: 奥村, 恭男 organization: 日本大学医学部内科学系循環器内科学分野 |
| BookMark | eNo9T8FKw0AUXKSCsfbmB_gDibsvm-4G8SBFq1Dwoudls9loQhslqQdvofWQoleLV1EQoSf1ogd_JqbRv7BV8TIzzMAMs4xq8UmsEVol2KLQpOvxWU9aHCwQjCwgg3BOTcyYW0MGxuCamAJdQo00DT3scOrajFIDbZSX158XeXU7Ka_G0-yhGr9PB3cfb_nXzVMxmBSD-2I4KoaPP-K5yDLAAGvl60s1ylfQYiC7qW78cR0d7mwftHbNzn57r7XVMSPCmDTB5b6jNJZcal8p1wPClC1BB4o6PPDsJnGDQDm-BzjwfM2UP8tmMz54wBS162jztzdK-_JIi9Mk7MnkXMikH6quFvPngoOAOTDy76tjmYhI2t-Ry2h8 |
| ContentType | Journal Article |
| Copyright | 2023 日本大学医学会 |
| Copyright_xml | – notice: 2023 日本大学医学会 |
| DOI | 10.4264/numa.82.2_71 |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1884-0779 |
| EndPage | 76 |
| ExternalDocumentID | article_numa_82_2_82_71_article_char_ja |
| GroupedDBID | 5GY ALMA_UNASSIGNED_HOLDINGS F5P JSF RJT |
| ID | FETCH-LOGICAL-j177a-298d5ce0a8aedcc9b217c3a2efc458fb3619ffc5db20fbde7cd2ef022d2b27c43 |
| ISSN | 0029-0424 |
| IngestDate | Wed Sep 03 06:30:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j177a-298d5ce0a8aedcc9b217c3a2efc458fb3619ffc5db20fbde7cd2ef022d2b27c43 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/numa/82/2/82_71/_article/-char/ja |
| PageCount | 6 |
| ParticipantIDs | jstage_primary_article_numa_82_2_82_71_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2023/04/01 |
| PublicationDateYYYYMMDD | 2023-04-01 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023/04/01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | 日大医学雑誌 |
| PublicationTitleAlternate | 日大医誌 |
| PublicationYear | 2023 |
| Publisher | 日本大学医学会 |
| Publisher_xml | – name: 日本大学医学会 |
| References | 5) Marston NA, Giugliano RP, Im K, et al. Association between 瀬在 明・他2 名 triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation 2019; 140: 1308–1317. 6) Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200: 135–140. 10) Pradhan AD, Glynn RJ, Fruchart JC, et al. Triglyceride lower ing with pemafibrate to reduce cardiovascular risk. New Engl J Med 2022; 387: 1923–1934. 12) 動脈硬化性疾患予防ガイドライン 2022年版，一般社団法人日本動脈硬化学会編集，東京，2017. 7) Sezai A, Unosawa S, Taoka M, et al. Long-term comparison of ethyl icosapentate vs. omega-3-acid ethyl in patients with car diovascular disease and hypertriglyceridemia (DEFAT trial). Circulation J 2019; 83: 1368–1376. 11) Ito H, Komuro I, Takeuchi M, et al. Intensive treat-to-target statin therapy in high-risk japanese patients with hypercho lesterolemia and diabetic retinopathy: report of a randomized study. Diabetes care 2018; 41: 1275–1284. 8) Hennuyer N, Duplan I, Paquet C, et al. The novel selective PPARα modulator(SPPARMα) pemafibrate improves dyslip idemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis 2016; 249: 200–208. 3) Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140–205. 14) Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278. 15) Kokubo Y, Nakamura S, Okamura T, et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the suita study. Stroke 2009; 40: 2674–2679. 1)動脈硬化性疾患予防ガイドライン 2022年版，一般社団法人日本動脈硬化学会編集，東京，2022. 2) Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124: S1–9. 4) Iso H, Imano H, Yamagishi K, et al. Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis 2014; 237: 361–368. 9) 木原 一．高中性脂肪血症患者に対するペマフィブラートの有効性と安全性─フィブラート系薬剤からの切り替 えにおける検討─．日大医誌 2022; 81: 99–102. 13) Giugliano RP, Pedersen TR, Park JG, et al. for the FOURIER investigators: Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 2017; 390: 1962–1971. |
| References_xml | – reference: 7) Sezai A, Unosawa S, Taoka M, et al. Long-term comparison of ethyl icosapentate vs. omega-3-acid ethyl in patients with car diovascular disease and hypertriglyceridemia (DEFAT trial). Circulation J 2019; 83: 1368–1376. – reference: 6) Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200: 135–140. – reference: 11) Ito H, Komuro I, Takeuchi M, et al. Intensive treat-to-target statin therapy in high-risk japanese patients with hypercho lesterolemia and diabetic retinopathy: report of a randomized study. Diabetes care 2018; 41: 1275–1284. – reference: 3) Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140–205. – reference: 15) Kokubo Y, Nakamura S, Okamura T, et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the suita study. Stroke 2009; 40: 2674–2679. – reference: 10) Pradhan AD, Glynn RJ, Fruchart JC, et al. Triglyceride lower ing with pemafibrate to reduce cardiovascular risk. New Engl J Med 2022; 387: 1923–1934. – reference: 4) Iso H, Imano H, Yamagishi K, et al. Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis 2014; 237: 361–368. – reference: 1)動脈硬化性疾患予防ガイドライン 2022年版，一般社団法人日本動脈硬化学会編集，東京，2022. – reference: 5) Marston NA, Giugliano RP, Im K, et al. Association between 瀬在 明・他2 名 triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation 2019; 140: 1308–1317. – reference: 14) Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278. – reference: 12) 動脈硬化性疾患予防ガイドライン 2022年版，一般社団法人日本動脈硬化学会編集，東京，2017. – reference: 2) Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124: S1–9. – reference: 9) 木原 一．高中性脂肪血症患者に対するペマフィブラートの有効性と安全性─フィブラート系薬剤からの切り替 えにおける検討─．日大医誌 2022; 81: 99–102. – reference: 8) Hennuyer N, Duplan I, Paquet C, et al. The novel selective PPARα modulator(SPPARMα) pemafibrate improves dyslip idemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis 2016; 249: 200–208. – reference: 13) Giugliano RP, Pedersen TR, Park JG, et al. for the FOURIER investigators: Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 2017; 390: 1962–1971. |
| SSID | ssib058493744 ssib004298531 ssib001535899 ssib007484389 ssj0000389138 ssib004001855 |
| Score | 2.3429663 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 71 |
| Title | 動脈硬化性疾患予防ガイドライン 2022 年版 |
| URI | https://www.jstage.jst.go.jp/article/numa/82/2/82_71/_article/-char/ja |
| Volume | 82 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日大医学雑誌, 2023/04/01, Vol.82(2), pp.71-76 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1884-0779 dateEnd: 99991231 omitProxy: true ssIdentifier: ssib007484389 issn: 0029-0424 databaseCode: KQ8 dateStart: 20080101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1Na9RAdKgVxIv4id_swTlJ1s1MMpnBU7JNKUoFocXeQjJJDgutIrsXT8vWwxa9WryKggg9qRc9-GfW7eq_8L1J0p1WD7UQwux8vI99k7w3mffmEXKn1CnH975TZEI7HisLB9ZZwnEFnndeyLT0MRp59ZFYWfcebPgbC6eeWF5Lg37W1i_-GVdyEqlCHcgVo2T_Q7IHQKECyiBfuIOE4X4sGdPYpzKiyqexpBKsQknjgIYuDbumqUuVoLFAb4YwwCb4GcWmhtGQ09ijUWhGKaokjRiNuWnqNgXPFOBSdSFUR5sibgoduBio6ruIOVI08hAhjKvy6TUGMCJXQKOP3QAG0mUojSJTs0RDYcgBtlxkKwQCD77kGh6A6I4hXWJ3mCIIEwdyA2oZ-LD7I_Pm71BdGsqmP7Ar43k3HylCoqBlCTHX3aSLkGusgf2JhHHLswYntcWZMLi6h1isOfubVwAMcgpt9cFwJ6kK-m4XlcaQEpAFVUacRqVIZj06zNIPVbqZ2tKoEt8c1WFoouKZuIPNtC1ZmyXNmEOngtdzDvPGpIlkCcNb4CZNPcbsJT1YOJxmgRCY2uPhY3t7lPv2dq-HuRl9e12twIybv_jxwFk-T0sARitYtbVdaEwes9stG3cq_IuqIBNk5p7NChh6PVj2NC6TxopbO0_O1cuvVljRf4Es9NKL5Mxq7WByidyfvnrz6-V49m5v-np3f_hxtvtjf_T-5_fx77efJ6O9yejDZHtnsv3JFL5MhkOc8q3pt6-znfFlsr4cr3VXnDq_iNNzgyB1gMnc10UnlWmRa60yWJ5rnrKi1J4vy4wLV5Wl9vOMdcosLwKdQxuAzVnGAu3xK2Rx6-lWcZW0uF8WosS4dYFO2RrUmsbDGfMc0zVIfY2Iiu3kWXWITHJMAV4_6cAb5Oz8UbhJFvvPB8UtsJ_72W0zF_4AxvOdsA |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%8B%95%E8%84%88%E7%A1%AC%E5%8C%96%E6%80%A7%E7%96%BE%E6%82%A3%E4%BA%88%E9%98%B2%E3%82%AC%E3%82%A4%E3%83%89%E3%83%A9%E3%82%A4%E3%83%B3%E3%80%802022+%E5%B9%B4%E7%89%88&rft.jtitle=%E6%97%A5%E5%A4%A7%E5%8C%BB%E5%AD%A6%E9%9B%91%E8%AA%8C&rft.au=%E7%94%B0%E4%B8%AD%2C+%E6%AD%A3%E5%8F%B2&rft.au=%E7%80%AC%E5%9C%A8%2C+%E6%98%8E&rft.au=%E5%A5%A5%E6%9D%91%2C+%E6%81%AD%E7%94%B7&rft.date=2023-04-01&rft.pub=%E6%97%A5%E6%9C%AC%E5%A4%A7%E5%AD%A6%E5%8C%BB%E5%AD%A6%E4%BC%9A&rft.issn=0029-0424&rft.eissn=1884-0779&rft.volume=82&rft.issue=2&rft.spage=71&rft.epage=76&rft_id=info:doi/10.4264%2Fnuma.82.2_71&rft.externalDocID=article_numa_82_2_82_71_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0029-0424&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0029-0424&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0029-0424&client=summon |